Why is the Nanosonics share price rocketing 10% today?

Investors are pleased with a big improvement in this company's performance.

| More on:
Man pointing at a blue rising share price graph.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Nanosonics Ltd (ASX: NAN) share price is having a very strong start to the week.

In morning trade, the infection control specialist's shares were up as much as 10% to $3.47.

Why is the Nanosonics share price surging 10%?

Investors have been fighting to get hold of the company's shares on Monday after it released a trading update.

According to the release, Nanosonics delivered strong growth in both capital and consumables/service revenue in the second half compared to the first.

This was particularly the case in the key North America market, which is getting investors excited today.

Management notes that this was driven by additional customer offerings to bridge budget constraints, a number of organisational changes in particular sales territory realignments, and a growing pipeline, together with improvements in sales conversion timelines.

Show me the money

Nanosonics revealed that it expects to report total revenue of approximately $170 million in FY 2024, which is an increase of 2.4% year on year.

This comprises first half revenue of $79.6 million and second half revenue of approximately $90.4 million. The latter represents a half on half increase of 14%.

Nanosonics' second half revenue growth was driven by a 20% half on half increase in capital revenue to $26.4 million and an 11% increase in consumables/service revenue to approximately $64 million.

The company also provided an update on its trophon footprint. It advised that a total of 3,850 trophon units were placed during the year, comprising 2,340 new installed base and 1,510 upgrade units.

For the second half, total units placed were 2,130, up 24% when compared with first half. Whereas new installed base units in the second half were 1,240, which is up 13% half on half. Upgrade unit sales were of 890 for the second half, up 44% on the first half.

The majority of this growth came from North America during the half, with total units placed up 28% to 1,850 and new installed base units up 6% to 1,030.

Nanosonics' CEO and President, Michael Kavanagh, was pleased with the performance. Especially given the challenging trading conditions. He said:

Despite a challenging market environment, the growth opportunity for trophon remains significant. With a growing pipeline for both new installed base and upgrades, it was pleasing to see the sales conversion timelines improve in the second half, which resulted in significant growth in H2 over H1 for capital unit sales.

The Nanosonics share price remains down by almost 30% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has positions in and has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Mesoblast just cleared a key FDA hurdle. So why are investors exiting?

Mesoblast shares slide to a 2-month low despite positive FDA feedback on its lead cell therapy product.

Read more »

Man leaps as he runs along the street.
Healthcare Shares

ASX 300 stock jumps 6% on strong half-year results and cash flow surge

Let's see how this medical device company performed during the first half.

Read more »

Two boys lie in the grass arm wrestling.
Healthcare Shares

Is CSL or Sonic Healthcare the smarter ASX healthcare share buy?

This ASX heavyweight has potential to deliver superior returns but is more volatile.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Up more than 800% in a year. Why this ASX medical tech stock just hit an all-time high

4DMedical shares have surged over 800% as US hospital adoption and FDA clearance drive momentum.

Read more »

A retiree relaxing in the pool and giving a thumbs up.
Healthcare Shares

1 ASX dividend stock down 36% I'd buy right now

This business looks like it’s priced too cheaply.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Why investors are watching this ASX healthcare stock

A fresh clinical update has been released.

Read more »

A Sonic Healthcare medical researcher wearing a white coat sits at her desk in a laboratory conducting a COVID-19 test
Healthcare Shares

This biotech is up more than 20% on new deal news

Revenue will flow under this global deal just announced.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

The next 3 years could be huge for this ASX healthcare stock. Here's why

Today's update has put this ASX healthcare stock back in the spotlight as investors reassess its long-term growth potential.

Read more »